Circle Pharma
athan is a passionate scientist with a broad background bridging the gaps between Chemistry, Biology, and Biochemistry. Nathan received his B.S. in Chemistry and Biology from Willamette University in Oregon where he started his research career in plant physiology under Gary Tallman. Nathan went on to earn his Ph.D. in UCSF’s Chemistry and Chemical Biology program under Jack Taunton, working on design and use of covalent protein kinase inhibitors. Nathan continued at UCSF as a postdoc, exploring kinases as drug targets in the parasite Trypanosoma brucei. After a brief stint in assay design and development, Nathan joined Unity Biotechnology in 2015 where he focused on new target ID and development to selectively kill senescent cells in diseases of aging.
This person is not in any offices
Circle Pharma
2 followers
Circle Pharma, Inc. initiated operations in June 2014 with seed funding from Pfizer, Inc. and Mission Bay Capital, LLP; we received additional seed funding from ShangPharma Investment Group Limited in November 2015. We recently raised Series B and Series C financing from The Column Group and NextTech Invest.